Prudential Financial
NRIX icon

Prudential Financial’s Nurix Therapeutics NRIX Stock Holding History

Prudential Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$685K Buy
+44,200
New +$733K ﹤0.01% 1743
2022
Q1 		– Sell
-41,495
Closed -$1.23M – 2665
2021
Q4 		$1.23M Buy
41,495
+12,775
+44% +$387K ﹤0.01% 1787
2021
Q3 		$861K Buy
28,720
+20
+0.1% +$617 ﹤0.01% 1893
2021
Q2 		$762K Buy
28,700
+750
+3% +$22K ﹤0.01% 1963
2021
Q1 		$869K Buy
+27,950
New +$1.06M ﹤0.01% 1901

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Prudential Financial's NRIX Position: Q1 2026 in Review

Prudential Financial opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 44,200 shares worth $685K. The stake represents ﹤0.01% of the portfolio and ranks #1743 among its holdings. This is a return to the name: Prudential Financial previously reported a position in NRIX as recently as Q4 2021.

Prudential Financial first reported a position in NRIX in Q1 2021 and has held it in 5 quarters since. The position peaked at $1.23M in Q4 2021. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Prudential Financial held 44,200 shares of Nurix Therapeutics worth $685K as of Q1 2026.
  • Nurix Therapeutics was a new Prudential Financial position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1743 holding.
  • Prudential Financial first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • Prudential Financial's Nurix Therapeutics position peaked at $1.23M in Q4 2021.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.